CD8A and malaria: In this study, we analyzed the peripheral PfCSP-specific CD4+ and CD8+ T cell responses in malaria-naive individuals vaccinated with Falciparum Malaria Protein 013 (FMP013), a nearly full-length recombinant PfCSP adjuvanted in Army Liposome Formulation containing QS21 (ALFQ), which induced strong antibody responses against the C terminus and gradually weaker responses against the central repeat and N-terminal domains in a recent phase I study (Hutter et al., 2022).